Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells.

Abstract : Allergic asthma is an inflammatory disease of the airways, resulting from an inappropriate immune response to inhaled allergens, which involves multiple inflammatory cells and mediators that contribute to airway hyper-responsiveness. Omalizumab is a monoclonal antibody, specifically directed to the C-Epsilon3 domain of immunoglobulin E (IgE), indicated as an additional therapy in severe allergic asthma [1]. Impaired function of regulatory T cells (Treg) is incriminated in the aberrant asthma inflammatory response [2].
Type de document :
Article dans une revue
Clinical and Experimental Allergy, Wiley, 2016, Epub ahead of print. 〈10.1111/cea.12839〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01404099
Contributeur : Flore Amat <>
Soumis le : lundi 28 novembre 2016 - 13:03:54
Dernière modification le : vendredi 14 septembre 2018 - 09:16:06

Identifiants

Citation

Flore Amat, Pauline Tallon, Anne Perrine Foray, Bénédicte Michaud, Nathalie Lambert, et al.. Control of asthma by omalizumab: the role of CD4(+) Foxp3(+) regulatory T cells.. Clinical and Experimental Allergy, Wiley, 2016, Epub ahead of print. 〈10.1111/cea.12839〉. 〈inserm-01404099〉

Partager

Métriques

Consultations de la notice

80